Evidence map›Paper›PMID 40806508›Full record

ArticleInternational journal of molecular sciences2025

Analysis of the Mitochondrial Dynamics in NAFLD: Drp1 as a Marker of Inflammation and Fibrosis.

Maël Padelli, Jocelyne Hamelin, Christophe Desterke, Mylène Sebagh, Raphael Saffroy, Claudio Garcia Sanchez, Audrey Coilly, Jean-Charles Duclos-Vallée, Didier Samuel, Antoinette Lemoine

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maël PadelliService de Biochimie et Oncogénétique, Hôpital Paul Brousse, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Saclay, 94800 Villejuif, France.ORCID 0000-0002-3103-1294
Jocelyne HamelinService de Biochimie et Oncogénétique, Hôpital Paul Brousse, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Saclay, 94800 Villejuif, France.
Christophe DesterkeFaculté de Médecine du Kremlin Bicêtre, Université Paris-Saclay, INSERM UMRS-1310, 94276 Le Kremlin-Bicêtre, France.ORCID 0000-0001-7679-2524
Mylène SebaghLaboratoire d'Anatomopathologie, Hôpital Paul Brousse, Assistance Publique-Hôpitaux de Paris (AP-HP), 94800 Villejuif, France.ORCID 0000-0002-6122-2542
Raphael SaffroyService de Biochimie et Oncogénétique, Hôpital Paul Brousse, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Saclay, 94800 Villejuif, France.
Claudio Garcia SanchezService de Biochimie et Oncogénétique, Hôpital Paul Brousse, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Saclay, 94800 Villejuif, France.
Audrey CoillyUMR-S 1193, Inserm, Physiopathogénèse et Traitement des Maladies du Foie, 94800 Villejuif, France.ORCID 0000-0003-3149-8617
Jean-Charles Duclos-ValléeUMR-S 1193, Inserm, Physiopathogénèse et Traitement des Maladies du Foie, 94800 Villejuif, France.
Didier SamuelUMR-S 1193, Inserm, Physiopathogénèse et Traitement des Maladies du Foie, 94800 Villejuif, France.
Antoinette LemoineService de Biochimie et Oncogénétique, Hôpital Paul Brousse, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Saclay, 94800 Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, projected to affect 55% globally by 2040. Up to one-third of NAFLD patients develop non-alcoholic steatohepatitis (NASH), with 40% progressing to fibrosis. However, there are currently few reliable tools to predict disease progression. Impaired mitochondrial dynamics, characterized by dysregulated fission, fusion, and mitophagy, have emerged as key events in NAFLD pathophysiology, contributing to hepatocyte death and inflammation. This study explored the transition from steatosis to NASH through transcriptomic analyses, including data from patients with steatosis and those with NASH at different fibrosis stages. By identifying a transcriptomic signature associated with disease progression, the study revealed increased expression of genes involved in mitochondrial dynamics in NASH compared to steatosis and during NASH-related fibrosis. Histological analyses highlighted the central role of Dynamin-related protein 1 (Drp1), a dynamin GTPase essential for mitochondrial fission and mitophagy. In human liver biopsies, Drp1 expression progressively increased from NAFLD to NASH and NASH-related fibrosis and cirrhosis, predominantly in Kupffer cells. These finding suggest Drp1 is a potential driver of the transition to more severe liver damage, making it a promising biomarker for NASH development and progression and a potential therapeutic target in metabolic disorders.

Indexed as

DynaminsInflammationLiver CirrhosisMitochondrial DynamicsNon-alcoholic Fatty Liver DiseaseBiomarkersDisease ProgressionFemaleHumansKupffer CellsLiverMaleMiddle AgedMitophagyTranscriptomeBiomarkersDNM1L protein, humanDynaminscirrhosisDrp1fibrosisKupffer cellsmitochondrial dynamicsmitochondrial fissionmitochondrial fusionmitophagynon-alcoholic fatty liver diseasenon-alcoholic steatohepatitis

Identifiers

PMID40806508
PMCPMC12347318

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.